Francois Bernard discussed the role of biosimilars at the Economist's Annual Pharma Summit
27 February 2015
The theme of this year’s Economist Events' 21st Annual Pharma Summit held in London in February was 'The Dawn of a New Era' in acknowledgement of the challenges the industry is facing as well as the innovation required to tackle them.
The event brought together over 200 leading voices representing global pharmaceutical companies, patient associations and regulators, who offered their perspectives on a number of topical issues, including Mundipharma’s Head of Market Access and Communications Dr Francois Bernard. Among the hot topics on the day were the current tensions between patient access to breakthrough treatments and the affordability to society of these innovations. Biosimilars came up high as a possible solution to help address the financial struggles of the healthcare system and disrupt the status quo.
Francois took part alongside Heidi Hunter, Head of Biosimilars Business Unit, Boehringer-Ingelheim, Jeremy Morgan, International Vice-president Diabetes, Lilly, Diem Nguyen, General Manager, Biosimilars, US Promoted Brands, LOE Portfolio Head, Pfizer and David Solomon, Chief Executive Officer, Bionor Pharma.
Francois shared with delegates that, “Biosimilars are an important solution for today’s financially-constrained world by satisfying the needs of payers as well as improving the lives of patients and the healthcare professionals who care for them” He continued, “It is our hope that these costs savings can be utilised to treat more patients and treat patients earlier in the disease pathway or to reallocate resources delivering better quality healthcare to patients.”